Aurobindo Pharma Ltd. (AUROPHARMA) Comprehensive Equity Report:
Aurobindo Pharma, a leading generics player with US/Europe focus, trades ₹1,090-1,100 as of Feb 7, 2026, ahead of Q3 FY26 results (Feb 9) and earnings call Feb 10. Report covers detailed technical/fundamental analysis, results outlook, news, and trading insights.
Detailed Technical Rationale:
Daily Overview: Strong Buy (7/9 buy signals): RSI 63.87 neutral-buy, MACD 7.54 Buy, STOCH 87.81 overbought (watch pullback), ADX 48.7 strong trend up; all 12 MAs bullish (price above EMA5-200).
Pivot Levels (5-min): Pivot ₹1,090.8, R1 ₹1,103.1–R2 ₹1,123.7–R3 ₹1,136; S1 ₹1,070.2–S2 ₹1,049.6–S3 ₹1,029.9—trading near R1, high volatility expected pre-results.
Trend: Uptrend intact above 50-DMA ~₹1,050, recent consolidation from ₹1,200 high; OBV rising confirms volume support. Enter long above ₹1,103 (R1) targeting ₹1,124–₹1,136, SL ₹1,070 (S1); post-results volatility 3-5% likely.
Detailed Fundamental Analysis:
Financials (FY25E): Revenue ₹31,724 Cr (+9.4% YoY), EBITDA ₹6,583 Cr (12.99%), PAT ₹3,486 Cr (+9.86%), EPS ₹59.6; ROE ~15%, ROCE 18%, debt moderate. Growth drivers: US generics (50% revenue, ARV/stable), Europe complex generics, oncology/hormonal R&D (depot injections tech); 150-country footprint via subsidiaries. Valuation P/E ~18-20x FY27E attractive vs. peers (Dr Reddy’s/Sun Pharma); risks: US pricing pressure, FDA inspections; positives: Pipeline 200+ ANDAs, PLI benefits.
Result Outlook (Feb 9, Call Feb 10):
Q3 FY26 expected: Revenue ₹8,382 Cr (11.65% YoY), EBITDA ₹1,792 Cr (13.94% margin), PAT ₹1,101 Cr (22.44% YoY), EPS ₹18.9—inline-to-beat on US volumes, Europe growth despite forex headwinds. Consensus: Revenue +11-13% YoY (QoQ +2%), margins stable 13-14%; beats if USFDA approvals/ARV demand noted. Management call (8:30 AM Feb 10, Zoom) key for FY26 guidance (revenue +10-12%, PAT +15%).
News Events & Impact:
Earnings call Feb 10 (pre-reg Zoom); recent Nuvama Chemicals/Healthcare Day (Jun 25); Investec/Goldman meetings—positive analyst interactions. No major negatives; pipeline oncology/derma updates expected. Impact: Beat = 8-12% rally to ₹1,200+ (R3 ₹1,136 test); miss on margins/US = drop to ₹1,050 support (3-7%).
Result Expectations & Stock Impact:
Expectations: Revenue inline ₹8,300-8,400 Cr, PAT beat potential ₹1,100 Cr+ on cost control; watch US share (50%+), guidance FY26 revenue ₹33-35k Cr.
Impact: Positive surprise (PAT >₹1,100 Cr, margin >14%) → upside to ₹1,150-1,200 (10%+); inline → rangebound ₹1,080-1,110; miss (US slowdown) → ₹1,030-1,050 (5-8% down). High volatility (ATR high), options skew call-heavy pre-results.
Disclaimer & Disclosure:
Educational report only; not investment advice. Risks apply; consult SEBI-RA. Author SEBI-registered; no holdings in Aurobindo Pharma/derivatives (Feb 7, 2026). SEBI (RA) Regs complied; public data.